Photographic assessment demonstrated that control IgG-treated Scl-cGVHD mice showed mild and diffuse alopecia throughout the entire body surface on day 42 after BMT; however, the area and severity of alopecia were clearly reduced by both 0.5 mg and 1 mg doses of anti-CX3CL1 mAb treatment (Fig. 1C). Here, CX3CL1 is linked to alopecia.